Hereditary nonpolyposis colorectal cancer secondary prevention: Difference between revisions
No edit summary |
|||
Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include genetic testing, colonoscopy, urine cytology, pelvic exam and endometrial biopsy. | Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include genetic testing, colonoscopy, urine cytology, pelvic exam and endometrial biopsy.<ref name="hnpcc">Kladny J, Lubinski J. Lynch syndrome (HNPCC). Hered Cancer Clin Pract. 2008;6(2):99-102.</ref> | ||
==Secondary prevention== | ==Secondary prevention== | ||
Recent studies demonstrate a reduced incidence in Lynch Syndrome patients who were exposed to at least four years of high-dose aspirin, with a satisfactory risk profile. These results have been widely covered in the media; future studies will look at modifying (lowering) the dose (to reduce risk associated with the high dosage of ASA). | Recent studies demonstrate a reduced incidence in Lynch Syndrome patients who were exposed to at least four years of high-dose aspirin, with a satisfactory risk profile. These results have been widely covered in the media; future studies will look at modifying (lowering) the dose (to reduce risk associated with the high dosage of ASA). | ||
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include: | Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include:<ref name="hnpcc">Kladny J, Lubinski J. Lynch syndrome (HNPCC). Hered Cancer Clin Pract. 2008;6(2):99-102.</ref> | ||
* Colonoscopy 25-35 years (2 years) | * Colonoscopy 25-35 years (2 years) |
Revision as of 17:47, 4 December 2015
Hereditary Nonpolyposis Colorectal Cancer Microchapters |
Differentiating Hereditary Nonpolyposis Colorectal Cancer from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hereditary nonpolyposis colorectal cancer secondary prevention On the Web |
American Roentgen Ray Society Images of Hereditary nonpolyposis colorectal cancer secondary prevention |
FDA on Hereditary nonpolyposis colorectal cancer secondary prevention |
CDC on Hereditary nonpolyposis colorectal cancer secondary prevention |
Hereditary nonpolyposis colorectal cancer secondary prevention in the news |
Blogs on Hereditary nonpolyposis colorectal cancer secondary prevention |
Directions to Hospitals Treating Hereditary nonpolyposis colorectal cancer |
Risk calculators and risk factors for Hereditary nonpolyposis colorectal cancer secondary prevention |
Overview
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include genetic testing, colonoscopy, urine cytology, pelvic exam and endometrial biopsy.[1]
Secondary prevention
Recent studies demonstrate a reduced incidence in Lynch Syndrome patients who were exposed to at least four years of high-dose aspirin, with a satisfactory risk profile. These results have been widely covered in the media; future studies will look at modifying (lowering) the dose (to reduce risk associated with the high dosage of ASA).
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include:[1]
- Colonoscopy 25-35 years (2 years)
- Pelvic exam, transvaginal ultrasound and CA-125 25-35 years (1 year)
- Endometrial biopsy
- Urine cytology - Families who have someone diagnosed with transitional cell carcinoma of the ureter or renal pelvis 25-35 years - (1 year)